Substances We Treat
How Does Suboxone Work? Understanding Opioid Treatment and Medication
Medically Reviewed By
Written By
Last medically reviewed July 14, 2025
Substances We Treat
Medically Reviewed By
Written By
Last medically reviewed July 14, 2025
Opioid Use Disorder (OUD) afflicts over 2.5 million adults in the US.[1] It’s a complex illness, and the urge to start using again can feel overwhelming. That’s because of drug cravings. These are intense urges to use opioids that can last for months or longer. Drug cravings are a major driver of relapse that feeds the cycle of addiction.
Fortunately, medication-assisted treatment (MAT) is a viable option for some recovery treatment plans.[2] MAT for OUD uses Suboxone, a medication that helps reduce cravings and makes long-term recovery possible.[3]
Suboxone is used in medication-assisted opioid treatment. It is an FDA-approved medication for the relief of withdrawal and cravings from opioid drugs.[4] Sublocade, Brixadi, and Subutex are also brand names for Suboxone. It’s a prescription-only combination of two medications: buprenorphine and naloxone.[5]
Opioid drugs work by binding to the mu-opioid receptors in your brain.[6] When these receptors are on, dopamine floods your brain, increasing feelings of pleasure and well-being. Additionally, when opioids are bound to these mu-opioid receptors, pain signals are suppressed.[7]
It works like this with typical opioids:[8]
Opioid drugs don’t create new dopamine. Instead, they take the brakes off the systems that regulate dopamine levels, causing them to skyrocket.[12]
Buprenorphine is a little different from other opioids.[13] It doesn’t cause intense euphoria. Although there may be a mild “lift” from taking it, it’s not highly intoxicating.[14] That’s because buprenorphine only partially binds to the receptor sites.
Think of it like a key stuck in a lock. The lock won’t open, and the means of opening the lock are blocked. Nothing can slide into the keyhole until it is unblocked. Buprenorphine sticks to the brain’s opioid receptors so firmly that other opioids can’t act on them.
Naloxone helps prevent Suboxone from being misused.[15] By itself, buprenorphine can magnify the euphoric effects, but paired with the opioid antagonist naloxone, it prevents this form of misuse.
If Suboxone is misused by being injected, it triggers precipitated withdrawal, preventing buprenorphine’s full opioid effect–in other words, no euphoria.[16] Precipitated withdrawal can be painful, even debilitating, which discourages misusing Suboxone.
You might wonder if naloxone is so good at knocking opioids out of the brain’s mu-opioid receptors, why isn’t buprenorphine affected?
Naloxone doesn’t “kick off” buprenorphine from the opioid receptors, especially when Suboxone is taken as prescribed (under the tongue).[17]
There are a few key reasons for this:
First, when Suboxone is taken sublingually (under the tongue), very little of the naloxone is absorbed into the bloodstream.[18] This means it doesn’t reach the brain in high enough amounts to have a significant effect on the buprenorphine that’s already there.
Second, buprenorphine has a very high “affinity” (which means it sticks very strongly) to the opioid receptors. It binds so tightly that it’s difficult for other opioids, even naloxone, to dislodge it once it’s attached.[19]
Third, buprenorphine has a long “half-life,” meaning it stays in the body and on the receptors for a long time (24 to 70 hours). Naloxone, on the other hand, has a very short half-life (around 30-40 minutes).[20] Even if some naloxone were to temporarily displace buprenorphine, its effects would be very short-lived.
However, if Suboxone is misused by injection or snorting, more naloxone is absorbed, and in these cases, the naloxone can indeed become active and trigger precipitated withdrawal.[21] This is why naloxone is included in Suboxone.
So, the difference is:
Suboxone comes in several forms, including a thin sublingual film.[22] You put it on the inside of your cheek (sublingual) or under your tongue. As it dissolves, it enters your bloodstream through the mucosal lining of your oral tissues.
Suboxone also comes in sublingual tablets. It may also be given as an injection.[23]
Suboxone helps people manage two painful problems that come from opioid use disorder: withdrawal and cravings.[24] Cravings to use opioids can feel irresistible. Withdrawal symptoms range from uncomfortable to debilitating. Withdrawal symptoms and opioid cravings diminish over time, but they are major relapse triggers until they do.[25]
When someone takes higher doses of opioids for longer than prescribed, their body builds tolerance.[26]This means they need more of the drug to feel the same effects. Over time, the brain reduces production of its natural chemical signals, including those that regulate dopamine.
Consequently, the person becomes dependent on the opioid drug to function normally and feel balanced.
Buprenorphine helps to reduce withdrawal symptoms and cravings, while naloxone blocks the effects of opioid drugs if someone attempts to misuse the medication. This combination allows patients to feel relief from withdrawal while also providing an extra layer of protection against relapse.
Addiction treatment of opioid dependency with buprenorphine produces the best results in combination with counseling services. Counseling services can include different forms and intensities of behavioral therapy and self-help programs.[27]
If you or a loved one is struggling with opioid use, help and healing are available. With tools like Suboxone, professional, compassionate therapy, and support, you can live the life you want.
Suboxone treatment is an effective option for people struggling with opioid use disorder.[28] However, whether it’s the right choice for a specific person depends on various factors. These include their medical history, the severity of their opioid dependence, and co-occurring mental health conditions. A qualified healthcare provider specializing in addiction treatment can assess an individual’s needs and determine if Suboxone is the most appropriate part of their treatment plan.
Common side effects include headache, constipation, nausea, and sweating.[29] Some people may also experience dizziness, insomnia, or irritability. Rare but serious side effects can include liver issues or allergic reactions. Always report new or worsening symptoms to your healthcare provider. Often, a healthcare provider can adjust the dosage to minimize or eliminate these side effects.
Many people can function normally while taking Suboxone, especially once stabilized. However, Suboxone can cause drowsiness or delayed reaction times in some individuals. Until you know how it affects you, avoid driving or operating heavy machinery.
The duration of Suboxone treatment varies greatly from person to person.[30] Some individuals may use Suboxone for a relatively short period to stabilize their withdrawal symptoms. Others will need to continue suboxone as they transition to other forms of recovery support. But many recovering individuals will benefit from long-term maintenance with Suboxone.
Only change your suboxone schedule under the instructions of your doctor. Stopping Suboxone suddenly can lead to uncomfortable withdrawal symptoms, similar to opioid withdrawal, although often less severe.[31]
These symptoms can include nausea, vomiting, muscle aches, insomnia, and intense cravings. It is always recommended to taper off Suboxone gradually under the supervision of a healthcare provider. A slow, controlled reduction (a taper) helps minimize withdrawal symptoms and increases the chances of maintaining long-term recovery.
Yes, Suboxone may be used during pregnancy, but only under close medical supervision.[32] Buprenorphine has been shown to reduce the risk of relapse in pregnant individuals and may be safer than full opioid agonists. However, naloxone’s safety during pregnancy isn’t well-established yet.[33]
Some providers may recommend switching to a buprenorphine-only product like Subutex.[34] The risks and benefits should be carefully discussed with a qualified healthcare provider.
Combining suboxone with other medications can be very dangerous.[35] Suboxone should not be combined with benzodiazepines (e.g., Xanax, Valium). Do not consume alcohol when taking Suboxone. Sedating antihistamines and other opioids should be avoided unless prescribed by a doctor. Always consult your doctor before combining Suboxone with other substances.
Avoid eating grapefruit or drinking grapefruit juice while taking Suboxone.[36] Grapefruit slows down the chemicals your body uses to break down buprenorphine. This can cause serious side effects, including heightened withdrawal symptoms.
[1] NIDA. 2023, August 7. Only 1 in 5 U.S. adults with opioid use disorder received medications to treat it in 2021. Retrieved from https://nida.nih.gov/news-events/news-releases/2023/08/only-1-in-5-us-adults-with-opioid-use-disorder-received-medications-to-treat-it-in-2021 on May 25, 2025
[2] Kleykamp, B. A., De Santis, M., Dworkin, R. H., Huhn, A. S., Kampman, K. M., Montoya, I. D., … & Strain, E. C. (2019). Craving and opioid use disorder: A scoping review. Drug and Alcohol Dependence, 205, 107639. Retrieved from https://www.sciencedirect.com/science/article/pii/S0376871619304168 on May 28th, 2025
[3] [4] [31] Drugs.com. (n.d.). Suboxone. Retrieved from https://www.drugs.com/suboxone.html on May 27, 2025
[5] World Health Organization. (2009). Clinical guidelines for withdrawal management and treatment of drug dependence in closed settings: 4, Withdrawal management. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK310652/ on May 28th, 2025
[6][7] National Institute on Drug Abuse. (n.d.). Opioids. Retrieved from https://nida.nih.gov/research-topics/opioids on May 28th, 2025.
[8] Cohen, B. (2023, April 29). Opioid analgesics. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK459161/
[9][25] Ugur, M., Derouiche, L., & Massotte, D. (2018). Heteromerization Modulates mu Opioid Receptor Functional Properties in vivo. Frontiers in Pharmacology, 9. Retrieved from https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.01240/full on May 28th, 2025
[10] Valentino, R.J., Volkow, N. Untangling the complexity of opioid receptor function. Neuropsychopharmacol 43, 2514–2520 (2018). Retrieved from https://doi.org/10.1038/s41386-018-0225-3 on May 28th, 2025
[11] Mental Health America. (n.d.). What is dopamine? Retrieved from https://mhanational.org/resources/what-is-dopamine/ on May 29, 2025.
[12] Berridge, K. C., & Kringelbach, M. L. (2015). Pleasure systems in the brain. Neuron, 86(3), 646–664. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC4425246/ on May 29, 2025.
[13] University of Arkansas for Medical Sciences. (n.d.). What is buprenorphine? Retrieved from https://psychiatry.uams.edu/clinical-care/outpatient-care/cast/buprenorphine/ on May 29, 2025.
[14] Mayo Clinic. (n.d.). Buprenorphine/naloxone (oromucosal route, sublingual route). Retrieved from https://www.mayoclinic.org/drugs-supplements/buprenorphine-naloxone-oromucosal-route-sublingual-route/description/drg-20074097 on May 29, 2025
[15] Drugs.com. (n.d.). Naloxone Hydrochloride Monograph for Professionals. Retrieved from https://www.drugs.com/monograph/naloxone-hydrochloride.html on May 28th, 2025
[16] [21] Soares WE, Schoenfeld E, Friedmann PD. Precipitated Withdrawal in the Era of Street Fentanyl—The Important Thing Is to Not Stop Questioning. JAMA Netw Open. 2024;7(9):e2435857. Retrieved from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824175 on May 29th, 2025
[17] California Department of Public Health. (n.d.). Naloxone. Retrieved from https://www.cdph.ca.gov/Programs/CCDPHP/sapb/pages/naloxone.aspx on May 30th, 2025
[18]Jordan, M. R., Patel, P., & Morrisonponce, D. (2024, May 5). Naloxone. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK441910/ on May 29, 2025
[19] Trøstheim, M., Eikemo, M., Haaker, J., Frost, J. J., & Leknes, S. (2022, August 17). Opioid antagonism in humans: A primer on Optimal Dose and timing for central MU-opioid receptor blockade. Nature News. https://www.nature.com/articles/s41386-022-01416-z
[20] NIDA. 2022, January 11. Naloxone DrugFacts. Retrieved from https://nida.nih.gov/publications/drugfacts/naloxone on May 29th, 2025
[22] Substance Abuse and Mental Health Services Administration. (n.d.). What is buprenorphine? Side effects, treatment & use. U.S. Department of Health and Human Services. Retrieved May 30, 2025, from https://www.samhsa.gov/substance-use/treatment/options/buprenorphine
[23]U.S. National Library of Medicine. (n.d.). Buprenorphine sublingual and buccal (opioid dependence): Medlineplus Drug Information. MedlinePlus. https://medlineplus.gov/druginfo/meds/a605002.html
[24] Ghosh, S., & Singh, R. (2021). Clinical and psychological factors associated with interdose opioid withdrawal in patients receiving buprenorphine. Journal of Substance Abuse Treatment, 129, 108379. Retrieved from https://www.sciencedirect.com/science/article/pii/S0740547221001124 on May 30th
[26] Institute for Chronic Pain. (n.d.). Tolerance to opioid pain medications. Retrieved from https://www.instituteforchronicpain.org/treating-common-pain/tolerance-to-opioid-pain-medications on May 30th, 2025
[27]Dugosh, K., Abraham, A., Seymour, B., McLoyd, K., Chalk, M., & Festinger, D. (2016). A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. Journal of addiction medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC4795974/
[28] National Institutes of Health. (2024, September 25). Higher doses of buprenorphine may improve treatment outcomes for people with opioid use disorder. Retrieved from https://www.nih.gov/news-events/news-releases/higher-doses-buprenorphine-may-improve-treatment-outcomes-people-opioid-use-disorder on May 30th, 2025
[29]You may be able to save on your next suboxone sublingual film prescription*†. Patient Information for SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII). (n.d.). https://www.suboxone.com/
[30] Williams, A. R., Samples, H., Crystal, S., & Olfson, M. (2020). Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. The American Journal of Psychiatry, 177(2), 117–124. Retrieved from https://psychiatryonline.org/doi/10.1176/appi.ajp.2019.19060612 on May 30th
[32] [35] Debelak, K., Morrone, W. R., O’Grady, K. E., & Jones, H. E. (2013). Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy—initial patient care and outcome data. The American Journal of Addiction, 22(3), 252–254. Retrieved from https://pubmed.ncbi.nlm.nih.gov/23617867/ on May 30th
[33]U.S. National Library of Medicine. (n.d.). Naloxone. MotherToBaby | Fact Sheets [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK582868/
[34] Oregon Health & Science University. (2022). Buprenorphine (Subutex) and Buprenorphine-naloxone (Suboxone) patient handout. Retrieved from https://www.ohsu.edu/sites/default/files/2022-08/Buprenorphine%20information%20patient%20handout.pdf on May 30th
[35] Physicians’ Desk Reference. (n.d.). Buprenorphine and Naloxone Sublingual Tablets – 2 mg/0.5 mg and 8 mg/2 mg – buprenorphine/naloxone. Retrieved from https://www.pdr.net/drug-summary/?drugLabelId=Buprenorphine-and-Naloxone-Sublingual-Tablets%E2%80%932-mg-0-5-mg-and-8-mg-2-mg%E2%80%93buprenorphine-naloxone-3772 on May 30th
[36] Ershad, M., Dela Cruz, M., Mostafa, A., McKeever, R., Vearrier, D., & Greenberg, M. I. (2020). Opioid toxidrome following grapefruit juice consumption in the setting of methadone maintenance. Journal of Addiction Medicine, 14(2), 172–174. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31206401/ on May 30th